<p>Prostate-specific membrane antigen positron emission tomography (PSMA PET) has galvanized progress in the field, opening the door to new possibilities for the treatment of advanced prostate cancer. At the 2025 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting, a series of presentations provided an overview of the theranostic clinical trial landscape. Oliver Sartor, MD, discusses his presentation on highlighted trials during the session, “Overview of Theranostic Trial Landscape With Clinical Impact in the Near Future – Part 2.”</p> <p> </p> <p> </p> <p>Following this presentation, featured expert Oliver Sartor, MD, was interviewed by Conference Reporter Editor-in-Chief Tom Iarocci, MD. Clinical perspectives from Dr Sartor on these findings are presented here.</p>